Infant Bacterial Therapeutics AB (publ) (IBT-B) — Cash Flow Quality Index

Latest as of June 2022: -17.11x

Infant Bacterial Therapeutics AB (publ) (IBT-B) has a Cash Flow Quality Index of -17.11x as of June 2022. Operating cash flow of Skr-30.09 Million is below net income of Skr1.76 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore IBT-B cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-17.11x

Operating CF / Net Income

Operating Cash Flow

Skr-30.09 Million

SEK

Net Income

Skr1.76 Million

SEK

Data as of

Jun 2022

Most recent filing

Annual Cash Flow Quality Index for Infant Bacterial Therapeutics AB (publ) (None–None)

Year-by-year earnings quality comparison for Infant Bacterial Therapeutics AB (publ).

Year	Quality Index	Operating CF (SEK)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.